11.61
0.17 (1.49%)
| Previous Close | 11.44 |
| Open | 11.52 |
| Volume | 525,933 |
| Avg. Volume (3M) | 841,233 |
| Market Cap | 4,102,938,880 |
| Price / Earnings (Forward) | 22.32 |
| Price / Sales | 0.890 |
| Price / Book | 0.680 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2025 |
| Profit Margin | -7.50% |
| Operating Margin (TTM) | -5.36% |
| Diluted EPS (TTM) | -1.02 |
| Quarterly Revenue Growth (YOY) | 3.50% |
| Total Debt/Equity (MRQ) | 75.07% |
| Current Ratio (MRQ) | 1.56 |
| Operating Cash Flow (TTM) | 166.00 M |
| Levered Free Cash Flow (TTM) | 69.00 M |
| Return on Assets (TTM) | 0.61% |
| Return on Equity (TTM) | -5.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | Bausch + Lomb Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.90 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 88.17% |
| % Held by Institutions | 11.01% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Clearline Capital Lp | 31 Mar 2025 | 893,790 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 17.00 (RBC Capital, 46.43%) | Buy |
| Median | 15.00 (29.20%) | |
| Low | 12.00 (Morgan Stanley, 3.36%) | Hold |
| 12.00 (Wells Fargo, 3.36%) | Hold | |
| Average | 14.44 (24.38%) | |
| Total | 3 Buy, 5 Hold | |
| Avg. Price @ Call | 11.78 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 09 Jun 2025 | 16.00 (37.81%) | Hold | 11.98 |
| Morgan Stanley | 06 May 2025 | 12.00 (3.36%) | Hold | 10.90 |
| HC Wainwright & Co. | 02 May 2025 | 15.00 (29.20%) | Buy | 11.50 |
| Citigroup | 01 May 2025 | 13.00 (11.97%) | Hold | 11.59 |
| Evercore ISI Group | 01 May 2025 | 15.50 (33.51%) | Buy | 11.59 |
| Wells Fargo | 01 May 2025 | 12.00 (3.36%) | Hold | 11.59 |
| 28 Mar 2025 | 15.00 (29.20%) | Hold | 14.13 | |
| RBC Capital | 04 Apr 2025 | 17.00 (46.43%) | Buy | 12.11 |
| Stifel | 03 Apr 2025 | 15.00 (29.20%) | Hold | 12.99 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BONNEFOY LUC | - | 12.33 | -968 | -11,935 |
| Aggregate Net Quantity | -968 | |||
| Aggregate Net Value ($) | -11,935 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 12.33 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BONNEFOY LUC | Officer | 13 Jun 2025 | Disposed (-) | 968 | 12.33 | 11,935 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |